# EDGAR Filing Document

**Accession Number:** 0001831283
**File Stem:** 0001831283-23-000043
**Filing Date:** 2023-3
**Character Count:** 16665
**Document Hash:** e2f3d63b050de69da7705d353d1c886a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001831283-23-000043.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001831283-23-000043

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**EFFECTIVENESS DATE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LianBio
- **CENTRAL INDEX KEY:** 0001831283
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270913
- **FILM NUMBER:** 23770776

**BUSINESS ADDRESS:**
- **STREET 1:** 103 CARNEGIE CENTER DRIVE, SUITE 309
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** (609) 486-2308

**MAIL ADDRESS:**
- **STREET 1:** 103 CARNEGIE CENTER DRIVE, SUITE 309
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**As filed with the Securities and Exchange Commission on March 28, 2023**

 **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

________________________

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

________________________

**LIANBIO**

**(Exact name of registrant as specified in its charter)**

________________________

---

| | |
|:---|:---|
| **Cayman Islands** | **98-1594670** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer <br>Identification No.) |

---

---

| | |
|:---|:---|
| **103 Carnegie Center Drive, Suite 309** | |
| **Princeton, NJ** | **08540** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**LianBio 2021 Equity Incentive Plan** 

(Full title of the plan)

**Yizhe Wang, Ph.D.**

**Chief Executive Officer**

**LianBio**

**103 Carnegie Center Drive, Suite 309**

**Princeton, New Jersey 08540**

**(609) 486-2308**

(Name, address and telephone number, including area code, of agent for service)

***with copies to:***

**Thomas J. Danielski**

**Ropes & Gray LLP**

**800 Boylston Street**

**Boston, Massachusetts 02199**

**(617) 951-7000**

________________________

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller reporting company ☒ |
| | Emerging growth company ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B)of the Securities Act. ☒

------

**EXPLANATORY NOTE**

This Registration Statement is being filed to register an additional 4,281,757 ordinary shares of the registrant for issuance under the LianBio 2021 Equity Incentive Plan. Pursuant to General Instruction E to Form S-8, the registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333-260732) filed with the Securities and Exchange Commission on November 3, 2021 and Form S-8 (File No. 333-264021) filed with the Securities and Exchange Commission on March 31, 2022.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 3.1 | <u>[Fifth Amended and Restated Memorandum and Articles of Association of LianBio (previously filed as Exhibit 3.1 to the current report on Form 8-K filed on November 3, 2021 (File No. 001-40947) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/0001831283/000119312521318383/d116576dex31.htm)</u> |
| 4.1 | <u>[Form of Deposit Agreement (previously filed as Exhibit 4.1 to the registration statement on Form S-1](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex41.htm)[filed on October 28, 2021](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex1035.htm)</u> <u>[(File No. 333-259978) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex41.htm)</u> |
| 4.2 | <u>[Form of American Depositary Receipt (previously filed as Exhibit 4.2 to the registration statement on Form S-1](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex41.htm)[filed on October 28, 2021](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex1035.htm)[(File No. 333-259978) and incorporated herein by reference.](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex41.htm)</u> |
| 4.3 | <u>[Specimen certificate evidencing ordinary shares (previously filed as Exhibit 4.4 to the registration statement on Form S-1 filed on October 28, 2021 (File No. 333-259978) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/0001831283/000119312521302493/d168979dex44.htm)</u> |
| 4.4 | <u>[LianBio 2021 Equity Incentive Plan (previously filed as Exhibit 10.35 to the registration statement on Form S-1 filed on October 28, 2021 (File No. 333-259978) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex1035.htm)</u> |
| 5.1\* | <u>[Opinion of Travers Thorp Alberga.](lianbio-sx8ex51opiniontta1.htm)</u> |
| 23.1\* | <u>[Consent of KPMG LLP](consentofkpmgllpforms-81.htm)</u> |
| 23.2\* | <u>[Consent of Travers Thorp Alberga (included in Exhibit 5.1).](lianbio-sx8ex51opiniontta1.htm)</u> |
| 24.1\* | <u>[Power of Attorney (included on the signature page of this Registration Statement under the caption "Power of Attorney").](#i3d4153c368f14166956ddd5e0759aa0c_7)</u> |
| 99.1 | <u>[Form of Non-Statutory Share Option Agreement (Non-Employee Directors) (previously filed as Exhibit 10.36 to the registration statement on Form S-1 filed on October 28, 2021 (File No. 333-259978) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1831283/000119312521295616/d168979dex1036.htm)</u> |
| 99.2# | <u>[Form of Non-Performance Based Restricted Share Unit Agreement (previously filed as Exhibit 10.41 to the Company's Annual Report on Form 10-K filed on March 31, 2022 (File No. 001-40947) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/0001831283/000183128322000014/exhibit1041-formofnonxperf.htm)</u> |
| 99.3# | <u>[Form of Performance Based Restricted Share Unit Agreement (previously filed as Exhibit 10.42 to the Company's Annual Report on Form 10-K filed on March 31, 2022 (File No. 001-40947) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/0001831283/000183128322000014/exhibit1042-formofperforma.htm)</u> |

---

&nbsp;&nbsp;&nbsp;&nbsp;

------

---

| | |
|:---|:---|
| 99.4# | <u>[Form of Non-Performance Based Share Option Agreement (Employees) (previously filed as Exhibit 10.43 to the Company's Annual Report on Form 10-K filed on March 31, 2022 (File No. 001-40947) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/0001831283/000183128322000014/exhibit1043-formofnonxperf.htm)</u> |
| 99.5# | <u>[Form of Performance Based Share Option Agreement (previously filed as Exhibit 10.44 to the Company's Annual Report on Form 10-K filed on March 31, 2022 (File No. 001-40947) and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/0001831283/000183128322000014/exhibit1044-formofperforma.htm)</u> |
| 107\* | <u>[Filing Fee Table](exhibit107filingfeetable1.htm)</u> |

---

\* Filed herewith. <br> # Indicates a management contract or any compensatory plan, contract or arrangement.

&nbsp;&nbsp;&nbsp;&nbsp;

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Princeton, New Jersey, on March 28, 2023.

---

| | |
|:---|:---|
| **LIANBIO** | **LIANBIO** |
| By: | /s/ Yizhe Wang |
|  | **Yizhe Wang** |
|  | **Chief Executive Officer and Director**<br>*(Principal Executive Officer)* |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Yizhe Wang and Yi Larson, and each of them, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by LianBio, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Yizhe Wang | Chief Executive Officer and Director (Principal Executive Officer) | March 28, 2023 |
| **Yizhe Wang, Ph.D.** | Chief Executive Officer and Director (Principal Executive Officer) | March 28, 2023 |
| /s/ Yi Larson | Chief Financial Officer (Principal Financial and Accounting Officer) | March 28, 2023 |
| **Yi Larson** | Chief Financial Officer (Principal Financial and Accounting Officer) | March 28, 2023 |
| /s/ Konstantin Poukalov | Director | March 28, 2023 |
| **Konstantin Poukalov** | Director | March 28, 2023 |
| /s/ Adam Stone | Director | March 28, 2023 |
| **Adam Stone** | Director | March 28, 2023 |
| /s/ Neil Kumar | Director | March 28, 2023 |
| **Neil Kumar, Ph. D.** | Director | March 28, 2023 |
| /s/ Tassos Gianakakos | Director | March 28, 2023 |
| **Tassos Gianakakos** | Director | March 28, 2023 |
| /s/ Susan Silbermann | Director | March 28, 2023 |
| **Susan Silbermann** | Director | March 28, 2023 |
| /s/ Wei Wei Chen | Director | March 28, 2023 |
| **Wei Wei Chen** | Director | March 28, 2023 |

---

------

**AUTHORIZED REPRESENTATIVE** 

Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this registration statement, solely in its capacity as the duly authorized representative of LianBio, in Princeton, New Jersey, on March 28, 2023.

---

| | |
|:---|:---|
| By | /s/ Yizhe Wang |
| Name: | Yizhe Wang, Ph.D. |
| Title: | Authorized Representative of LianBio |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**LianBio**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Share**<sup>(4)</sup> | **Maximum Aggregate Offering Price**<sup>(4)</sup> | **Fee Rate** | **Amount of Registration Fee**<sup>(4)</sup> |
| Equity | Ordinary shares, par value $0. 000017100448 per share<sup>(2)</sup> | 457(c) and 457(h) | 4281757<sup>(3)</sup> | $1.72 | $7364622.04 | 0.0001102 | $811.58 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $7364622.04 |  | $811.58 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $- |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $811.58 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional ordinary shares as may issued to prevent dilution from stock splits, stock dividends and similar transactions.

(2) These shares may be represented by the Registrant's American depositary shares ("ADSs"), each of which represents one ordinary share. The Registrant's ADSs issuable upon deposit of the ordinary shares registered hereby have been registered under a separate registration statement on Form F-6 (File No. 333-260162).

(3) Represents 4,281,757 ordinary shares that were automatically added to the shares authorized for issuance upon exercise of options or in respect of other awards under the LianBio 2021 Equity Incentive Plan (the "2021 Plan") pursuant to an "evergreen" provision contained in the 2021 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2022 through January 1, 2031, the number of ordinary shares available for issuance under the 2021 Plan will automatically increase annually in an amount equal to the lesser of 4% of outstanding shares of the Registrant's ordinary shares as of the close of business on the immediately preceding December 31st, or the number of shares determined by the Registrant's board of directors.

(4) Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's ADSs as reported on the Nasdaq Global Market on March 23, 2023 to be $1.76 and $1.67, respectively.

## Exhibit 5.1

![ex51logo.jpg](ex51logo.jpg)

**Office:**&nbsp;&nbsp;&nbsp;&nbsp;+852 2801 6066

**Mobile:**&nbsp;&nbsp;&nbsp;&nbsp;+852 9718 8740

**Email:**&nbsp;&nbsp;&nbsp;&nbsp;rthorp@tta.lawyer

LianBio

Harbour Place, 2nd Floor

103 South Church Street

P.O. Box 472, George Town

Grand Cayman KYI-1106

Cayman Islands

28 March 2023

Dear Sirs

**LianBio** 

We have examined the Registration Statement on Form S-8 to be filed by LianBio, a Cayman Islands exempted company incorporated with limited liability (the "**Registrant**"), with the Securities and Exchange Commission (the "**Registration Statement**"), relating to the registration under the Securities Act of 1933, as amended, of an amount of ordinary shares of the Registrant (the "**Shares**") for issuance pursuant to the LianBio 2021 Equity Incentive Plan (the "**Plan**").

As Cayman Islands counsel to the Registrant, we have examined the corporate authorisations of the Registrant in connection with the Plan and the issue of the Shares by the Registrant and have assumed that the Shares will be issued in accordance with the Plan and the resolutions authorizing the issue.

It is our opinion that the Shares to be issued by the Registrant have been duly and validly authorised, and when issued, sold and paid for in the manner described in the Plan and in accordance with the relevant resolutions adopted by the Board of Directors and/or the shareholders of the Registrant (or any committee to whom the Board of Directors have delegated their powers with respect to administration of the Plan) and when appropriate entries have been made in the Register of Members of the Registrant, will be legally issued, fully paid and non-assessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us in the Registration Statement and any amendments thereto.

Yours faithfully

/s/ Travers Thorp Alberga

**TRAVERS THORP ALBERGA**

![image_1.jpg](image_1.jpg)

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 28, 2023, with respect to the consolidated financial statements of LianBio and subsidiaries, incorporated herein by reference.

/s/ KPMG LLP

New York, New York

March 28, 2023

<br>